20 . 03 .2026
Press release
Galderma publishes invitation and agenda for its 2026 Annual General Meeting
17 . 03 .2026
Press release
AMWC 2026: Galderma showcases category‑leading innovation with a comprehensive portfolio and holistic, future‑focused aesthetic strategies
11 . 03 .2026
Press release
Galderma completes successful placement of EUR 500 million Eurobond
09 . 03 .2026
Press release
Galderma introduces Cetaphil AM/PM Antioxidant Serums, a new science-driven defense and recovery system for sensitive skin
27 . 02 .2026
Press release
Galderma’s Nemluvio® (nemolizumab) demonstrates long-term disease control in prurigo nodularis up to three years
25 . 02 .2026
Press release
Galderma announces triple approval of new state-of-the-art Restylane® syringe in the EU, the U.S., and Canada, reaffirming the company’s position at the forefront of Injectable Aesthetics
12 . 02 .2026
Press release
We Are All Sculptra: first-of-its-kind Galderma initiative to demonstrate how everyone can benefit from Sculptra’s regenerative properties
11 . 02 .2026
Press release
Galderma expands Restylane® portfolio in Japan with launch of OBT™ hyaluronic acid injectables Restylane Defyne™ and Refyne™
02 . 02 .2026
Press release
Galderma announces U.S. FDA acceptance of RelabotulinumtoxinA Biologics License Application resubmission
30 . 01 .2026
Press release
Galderma tackles menopause-related skin changes with global survey and clinical trial inclusivity